We need your views! Help us help you.
The Managed Healthcare Executive Annual Pharmacy Survey gives us insights into your opinions and judgments about the most important — and sometimes controversial — issues in the pharmaceutical side of managed care.
Those insights help MHE editors and staff understand our readership, so our coverage is relevant, informative, useful and smart.
And you’ll see the results, so you can draw your own inferences and come to your own conclusions. We will publish them in our May print publication and on our website next month.
From biosimilars to PBM transparency to managing the skyrocketing cost GLP-1s — the intersection of managed care and pharmaceutical issues has never been busier.
Hurry and fill out the survey now! The first 25 respondents are guaranteed a $10 gift card. Click the link below and be one of the first to take the survey. It only takes a few minutes to complete.
Click here to fill out the Managed Healthcare Executive 2024 Annual Pharmacy Survey .
Thank you!
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More